The skin pigment lightening properties of HQ appear to be due to inhibition of melanocyte tyrosinase (Fig. 1) . 1, 9) Recent investigations have suggested the nephrotoxicity, mutagenicity or carcinogenicity of HQ. 1, [8] [9] [10] However, the adverse events associated with external OTC use of HQ in FDA-regulated products have been limited to a small number of cases of exogenous ochronosis, whereas higher incidences have been reported with inappropriate use of unregulated OTC products containing higher HQ concentrations. 1) In Japan, HQ formulations are not commercially available and have been prepared by extemporaneous nonsterile compounding in hospitals with various prescriptions without sufficient experimental evidence providing justification for the prescriptions.
HQ-containing ointments were first introduced at Kobe University Hospital, Japan, in 1998 (Table 1) . During their usage for about 3 years, various problems have been ob- served including 1) chromatic aberration of HQ ointments, 2) relatively large variability of efficacy, and 3) undesirable adverse events including irritation although they were mild. Chromatic aberration is easily expected to induce non-compliance of the ointment, and this can be the reason for the relatively large variability of the efficacy. In this study, the effect of 3 month storage on the chromatic aberration of HQ ointments, and alterations of HQ and p-benzoquinone (p-BQ) contents in the ointment was evaluated as well as the clinical efficacy. HQ is susceptible to acid-base and oxidation-reduction matrix to form various chemical structures including p-BQ. 1) p-BQ is thought to be potentially important for the action of HQ in biological systems, 1) and is expected to be responsible for the chromatic aberration of HQ ointment.
Pharmaceutical and Clinical Assessment of Hydroquinone Ointment Prepared by Extemporaneous Nonsterile Compounding

MATERIALS AND METHODS
Chemicals HQ and L(ϩ)-ascorbic acid (AsA) were purchased from Nacalai Tesque, Inc., Kyoto, Japan. Sodium sulfite anhydrous (Na 2 SO 3 ) was from Wako Pure Chemical Industries, Ltd., Osaka, Japan. Glycerin (JP grade) was from Nippon Shinyaku Co., Ltd., Kyoto, Japan. Hydrophilic ointment (JP grade) was from Merck-Hoei Ltd., Osaka, Japan. Other chemicals were of the highest purity available.
Preparations of HQ Ointments For clinical use (Rp. 5100 or 10100), HQ (5 or 10 g, respectively), AsA (1.6 g), and Na 2 SO 3 (0.5 g) were mixed in a mortar, followed by addition of 10 ml of glycerin to make a suspension. The suspension was mixed with hydrophilic ointment to give 100 g of HQ ointment. Extemporaneous nonsterile compound of HQ ointment was packed as 10 g per patient. One percent HQ ointment (Rp. 1100) was also prepared for hypersensitive patients, if necessary.
In this study, various types of HQ ointments were prepared for pharmaceutical assessment, including antioxidant-free HQ ointments (Rp. 1200, 5200, 10200) and acidic HQ ointments (Rp. 5300, 5310, 5320, and 5330) ( Table 2) .
Chromatic Aberration of HQ Ointments Various types of HQ ointments were stored at 4°C or 25°C for a maximum of 3 months, and the chromatic aberration of the HQ ointment was evaluated spectrophotometrically. HQ ointments (0.2 g) were sampled from the center area on the surface of the ointment and added to 5.0 ml of dimethylsulfoxide (DMSO), followed by mixing on a vortex mixer for 15 s. After centrifugation for 10 min at 3000 rpm (950ϫg) at room temperature, the supernatant was filtered through a 0.45 mm filter (MILLEX-HV, Millipore S.A., France), and immediately the absorption was determined at 400 nm with reference to that of DMSO.
Alterations of HQ and p-BQ Contents in HQ Ointments Alterations of HQ and p-BQ contents were also evaluated by HPLC. HQ ointments (0.2 g) were added to 5.0 ml of DMSO, and mixed on a vortex mixer for 15 s. The supernatant after centrifugation was diluted with 20 volumes of methanol and injected into an HPLC system; Shimadzu LC-10A system (system controller SCL-10A; detector SPD-10A; pump LC-10AT; autoinjector SIL-10AXL; degasser DGU-4A; column oven CTO-10A; integrator C-R7A). The reverse phase assay was conducted using a column of CHEM-COBOND 5-ODS-H (250ϫ4.6 mm, Chemco Scientific Co., Ltd., Japan). A mixture of 0.01 M sodium dihydrogenphosphate (adjusted to pH 3.0 by 0.01 M phosphate) and methanol (volume ratio of 95 : 5) was used as the mobile phase. The flow rate was 1.5 ml/min. The column was maintained at 35°C
. HQ and p-BQ were detected at 252 nm, and their retention times were 7.3 min and 16.3 min, respectively. A standard line was constructed for each assay. It was confirmed that there were minimum within-day and day-to-day variations in the standard line, ensuring acceptable accuracy and precision.
Acidity of HQ Ointments HQ ointments (2.0 g) were added to 8.0 ml of purified water, and mixed on a vortex mixer for 15 s, followed by heating in a boiling water bath for 5 min. After cooling to room temperature, the pH values were determined.
Clinical Evaluation of Efficacy of HQ Ointments Thirty patients were selected to assess the effects of HQ ointments based on the following criteria: 1) out-patients of Kobe University Hospital, Japan; 2) receiving basic treatment with 5% HQ ointment (Rp. 5100), and 10% HQ ointment (Rp. 10100) if the doctor had judged the effects of 5% HQ ointment to be insufficient; and 3) no treatment with other externally medicines applied. Ten grams of HQ ointment was given to each patient. Medical doctors directed the patients to store the ointment in the refrigerator and use maximally twice a day for one month. Clinical efficacy was evaluated by a medical doctor in the Department of Dermatology, Kobe University Hospital, Japan.
Chromatic Aberration and 1 H-NMR Analysis of HQ and p-BQ Aqueous Solutions Aqueous solutions of HQ (10 mg/ml) and p-BQ (10 mg/ml) were mixed at various volume ratios, and the absorption at 400 nm and pH values determined. HQ and p-BQ were also dissolved in D 2 O or DMSO-d 6 , and their solutions were mixed and analyzed by 1 H-NMR (JEOL JNM-LA 500 spectrometer, JEOL, Japan).
Statistical Analysis All data presented are the meanϮS.D. Equivalence of variance was tested by F-test. Table 3 lists the results of the clinical evaluation of HQ ointment in the outpatients who received basic treatment with 5% HQ ointment (Rp. 5100), and 10% HQ ointment (Rp. 10100) if the effects of 5% HQ ointment were judged to be insufficient. Clinical efficacy was evaluated by a medical doctor in the Department of Dermatology, Kobe University Hospital, Japan, based on the degree of depigmentation. HQ ointment was found to be effective in 24 of 30 patients.
RESULTS
Clinical Efficacy of HQ Ointments
Chromatic Aberration and Alterations of HQ and p-BQ Contents in HQ Ointments for Clinical Use Figure 2 shows the time-dependent alterations in the absorption spectrum of 5% HQ ointment stored at 4°C for 3 months. Ultraviolet absorption increased gradually with storage time. The absorption at 400 nm increased time-dependently and was higher with storage at 25°C than 4°C (Table 4 ). This chromatic aberration was independent of prescribed HQ contents (Table 4 ). HQ and p-BQ contents altered time-independently, and almost maintained the initial contents, suggesting segregation of HQ and p-BQ (Table 4) . Time-dependent chromatic aberration of HQ ointments was not due to alterations of HQ and p-BQ contents.
Chromatic Aberration and Alterations of HQ and p-BQ Contents in Antioxidant-free HQ Ointments Table 5 shows the chromatic aberration and alterations of HQ and p-BQ contents in antioxidant-free HQ ointments. Similarly to HQ ointments for clinical use, the absorption at 400 nm increased with storage time, and was suppressed at 4°C compared with 25°C. Chromatic aberration was independent of prescribed HQ contents, and was not explained by alterations of HQ and p-BQ contents. Compared with HQ ointments for clinical use, the chromatic aberration was suppressed, but p-BQ content was increased by removing the antioxidants, AsA Table 6 shows the chromatic aberration and alterations of HQ and p-BQ contents in acidic HQ ointments. The pH values were also monitored during 3 months of storage, and were confirmed to be maintained over this period (data was not shown). Similarly to HQ ointments for clinical use, the absorption at 400 nm increased during storage, and was suppressed at 4°C. Chromatic aberration was independent of HQ and p-BQ contents. Acidification by removal of Na 2 SO 3 resulted in extensive suppression of chromatic aberration and higher initial contents of p-BQ. However, p-BQ content decreased to almost zero in a time-dependent manner.
Chromatic Aberration and 1 H-NMR Analysis of HQ and p-BQ Aqueous Solutions
The mixing of aqueous solutions of HQ (10 mg/ml) and p-BQ (10 mg/ml) resulted in immediate and spontaneous precipitation of a dark brown material with a light brown supernatant. The precipitation was remarkable at the volume ratio of HQ solution: p-BQ solutionϭ5 : 3 to 1 : 1. Figure 3 shows the absorption at 400 nm and pH values of the supernatant after storage of the mixtures for 24 h. The absorption at 400 nm was due to p-BQ concentration. HQ and p-BQ were dissolved in D 2 O at the concentration of 16.7 mg/ml and 10 mg/ml, respectively, and their mixing at volume ratio of 1 : 1 resulted in precipitation of a dark brown material with a light brown supernatant. This precipitate was isolated by centrifugation and dissolved in 
DISCUSSION
In the hospital, various types of extemporaneous nonsterile compounds have been prepared to individualize drug therapy for specific patients, including half cut or crushed-ground products of commercially available tablets, blended formulations of powder drugs, topical dermatological ointments and creams, rectal and vaginal suppositories, oral suspensions, and oral jelly formulations of drugs. In most cases, the prescription and production method were empirically determined without sufficient experimental evidence providing justification for the prescriptions, and varied depending on the doctor or hospital policy. The batch size should be small enough to ensure all final compounding products will be used prior to their expiration, but large enough to avoid preparing additional batches in the immediate future. Information pertinent to quality assurance should be elucidated in the hospital, e.g. stability of drugs and formulations.
In Japan, HQ ointments have been prepared by extemporaneous nonsterile compounding in hospitals by imitating skin lightening creams commercially available in the U.S.A. and European Union. In this study, the HQ ointments used in our hospital were subjected to pharmaceutical and clinical assessment. It was suggested that chromatic aberration would occur during storage and was independent of prescribed HQ contents, but this could be suppressed by storage at 4°C. Unexpectedly, removal of antioxidants, AsA and Na 2 SO 3 , resulted in suppression of chromatic aberration, but an increase in p-BQ content. Acidification of the HQ ointments by removal of Na 2 SO 3 only was further effective for the suppression of chromatic aberration. In this case, p-BQ contents was also decreased except in the initial period. Based on these results, alteration of prescriptions can be performed provided Table 6 . Chromatic Aberration and Alteration of HQ and p-BQ Contents in Acidic HQ Ointments that p-BQ or acidification has no effect on the safety and efficacy of the HQ ointments.
Chromatic aberration found in the HQ ointments for clinical use was not explained by the alterations of HQ and p-BQ contents. There were no peaks on HPLC chromatograms at 252 nm even for the HQ ointments with extensive chromatic aberration. The chromatic aberration of the HQ ointments was due to water soluble material and insoluble material both formed by co-existence of HQ and p-BQ at molecular ratio of 5 : 3 to 1 : 1.
1 H-NMR analysis elucidated that the water soluble material was not HQ or p-BQ and the insoluble material was a complex of HQ and p-BQ with non-covalent binding.
Recent studies suggested the possibility of serious adverse events associated with HQ, 1, [8] [9] [10] and various types of skinlightening agents have been proposed including gentisic acid analogues, 9) HQ glucosides 11) and tert-butyl HQ. 12) New protocols or formulation methods have also been proposed using all-trans retinoic acid, kojic acid and hydrocortisone. [13] [14] [15] With progression of assay systems for depigmentation of candidate drugs, 16, 17) these agents will be included in topical medicines, but extemporaneous nonsterile compounding of HQ ointments has been found to be sufficient to treat various types of pigmentation (Table 3) .
